{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:19:48Z","timestamp":1792466388727,"version":"4.5.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The optimal means of assessing candidacy of older adults (\u226565 years) for chimeric antigen receptor T-cell (CAR-T) therapy are unknown. We explored the role of a geriatric assessment (GA)\u2013guided multidisciplinary clinic (GA-MDC) in selecting and optimizing older adults for CAR-T. Sixty-one patients were evaluated in a GA-MDC (median age, 73 years; range, 58-83). A nonbinding recommendation (\u201cproceed\u201d or \u201cdecline\u201d) regarding suitability for CAR-T was provided for each patient based on GA results. Fifty-three patients ultimately received CAR-T (proceed, n\u00a0=\u00a047; decline, n\u00a0=\u00a06). Among patients who received B-cell maturation antigen (BCMA)\u2013directed (n\u00a0=\u00a011) and CD19-directed CAR-T (n\u00a0=\u00a042), the median overall survival (OS) was 14.2\u00a0months and 16.6\u00a0months, respectively. GA uncovered high rates of geriatric impairment among patients proceeding to CAR-T therapy, with fewer impairments in those recommended \u201cproceed.\u201d Patients recommended \u201cproceed\u201d had shorter median length of stay (17 vs 31\u00a0days; P\u00a0=\u00a0.05) and lower rates of intensive care unit admission (6% vs 50%; P\u00a0=\u00a0.01) than those recommended \u201cdecline.\u201d In patients receiving CD19- and BCMA\u2013directed CAR-T therapy, a \u201cproceed\u201d recommendation was associated with superior OS compared with \u201cdecline\u201d (median, 16.6 vs 11.4\u00a0months [P\u00a0=\u00a0.02]; and median, 16.4 vs 4.2\u00a0months [P\u00a0=\u00a0.03], respectively). When controlling for Karnofsky performance status, C-reactive protein, and lactate dehydrogenase at time of lymphodepletion, the GA-MDC treatment recommendation remained prognostic for OS (hazard ratio, 3.26; P\u00a0=\u00a0.04). Patients optimized via the GA-MDC without serious vulnerabilities achieved promising outcomes, whereas patients with high vulnerability experienced high toxicity and poor outcomes after CAR-T therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012727","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T20:56:00Z","timestamp":1717016160000},"page":"3785-3797","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Optimization of older adults by a geriatric assessment\u2013guided multidisciplinary clinic before CAR T-cell therapy"],"prefix":"10.1182","volume":"8","author":[{"given":"Samuel J.","family":"Yates","sequence":"first","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-1767","authenticated-orcid":false,"given":"John F.","family":"Cursio","sequence":"additional","affiliation":[{"name":"2Department of Public Health Sciences, University of Chicago Biological Sciences Division, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keriann","family":"Kordas","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"},{"name":"4The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Kosuri","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylove","family":"Mortel","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalitha","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5161-0878","authenticated-orcid":false,"given":"Mariam T.","family":"Nawas","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"7","key":"2024072313061530800_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024072313061530800_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2024072313061530800_bib3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"2024072313061530800_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2024072313061530800_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2024072313061530800_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024072313061530800_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024072313061530800_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2024072313061530800_bib9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2024072313061530800_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41409-018-0164-y","article-title":"Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia","volume":"53","author":"Bhatt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024072313061530800_bib11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024072313061530800_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2024072313061530800_bib13","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024072313061530800_bib14","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024072313061530800_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2024072313061530800_bib16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2023-173873","article-title":"Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: a subgroup analysis of ZUMA-7","volume":"142","author":"Kersten","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2024072313061530800_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","article-title":"CAR T-cell therapy in the older person: indications and risks","volume":"24","author":"Shouse","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"suppl 1","key":"2024072313061530800_bib18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2021-150858","article-title":"Physical therapy assessment of baseline function and endurance predicts short term outcomes in commercial CAR T patients with lymphoma","volume":"138","author":"Shouse","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024072313061530800_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2022-163822","article-title":"Consensus cachexia criteria are independently linked to progression free and overall survival in multi-site analysis of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy","volume":"140","author":"Roy","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024072313061530800_bib20","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood-2021-149784","article-title":"Sarcopenia is a clinically relevant and independent predictor of health outcomes after chimeric antigen receptor T-cell therapy for lymphoma","volume":"138","author":"Iukuridze","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2024072313061530800_bib21","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2024072313061530800_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/10428194.2021.1986216","article-title":"Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2024072313061530800_bib23","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A\u00a0validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024072313061530800_bib24","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2024072313061530800_bib25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbmt.2012.11.006","article-title":"Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients","volume":"19","author":"Muffly","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2024072313061530800_bib26","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","article-title":"Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults","volume":"3","author":"Derman","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2024072313061530800_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jgo.2020.10.019","article-title":"Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients","volume":"12","author":"Derman","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"10","key":"2024072313061530800_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024072313061530800_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.6004\/jnccn.2015.0137","article-title":"Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts","volume":"13","author":"Mohile","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"2024072313061530800_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \"Up & Go\": a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"6","key":"2024072313061530800_bib44","first-page":"387","article-title":"Balance in elderly patients: the \"get-up and go\" test","volume":"67","author":"Mathias","year":"1986","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"2024072313061530800_bib45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1634\/theoncologist.2015-0200","article-title":"Prognostic importance of pretransplant functional capacity after allogeneic hematopoietic cell transplantation","volume":"20","author":"Jones","year":"2015","journal-title":"Oncol"},{"issue":"5","key":"2024072313061530800_bib46","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1034\/j.1600-0579.2003.00207.x","article-title":"Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism","volume":"51","author":"Rantanen","year":"2003","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"2024072313061530800_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontol"},{"key":"2024072313061530800_bib48","first-page":"3","volume-title":"Measuring Functioning and Well-Being: The Medical Outcomes Study Approach","year":"1992"},{"issue":"3","key":"2024072313061530800_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.1994.12.3.601","article-title":"Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"2024072313061530800_bib50","first-page":"196","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"issue":"6","key":"2024072313061530800_bib51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1176\/ajp.140.6.734","article-title":"Validation of a short orientation-memory-concentration test of cognitive impairment","volume":"140","author":"Katzman","year":"1983","journal-title":"Am J Psychiatr"},{"issue":"4","key":"2024072313061530800_bib52","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"2","key":"2024072313061530800_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jgo.2018.08.009","article-title":"Mental status evaluation in older adults with cancer: development of the Mental Health Index-13","volume":"10","author":"Pergolotti","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"1","key":"2024072313061530800_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.18054","article-title":"Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"197","author":"Roy","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"2024072313061530800_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/01635581.2020.1749290","article-title":"Modified Glasgow prognostic score, prognostic nutritional index and ECOG performance score predicts survival better than sarcopenia, cachexia and some inflammatory indices in metastatic gastric cancer","volume":"73","author":"Demirelli","year":"2021","journal-title":"Nutr Cancer"},{"issue":"4","key":"2024072313061530800_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024072313061530800_bib31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024072313061530800_bib32","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024072313061530800_bib33","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024072313061530800_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"2024072313061530800_bib36","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/bloodadvances.2023010003","article-title":"Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older lymphoma patients","volume":"7","author":"Lin","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2024072313061530800_bib37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-23-0313","article-title":"Linking body composition and nutritional status with CAR T-cell efficacy","volume":"11","author":"Nawas","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"2024072313061530800_bib38","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024072313061530800_bib39","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/blood-2022-163750","article-title":"Impact of age on outcomes after CD19 directed CAR T cell therapy for large B cell lymphomas: real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)","volume":"140","author":"Mirza","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2024072313061530800_bib40","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024072313061530800_bib41","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2024072313061530800_bib42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3785\/2235671\/blooda_adv-2024-012727-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3785\/2235671\/blooda_adv-2024-012727-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:40:07Z","timestamp":1721742007000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/14\/3785\/516267\/Optimization-of-older-adults-by-a-geriatric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":54,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012727","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}